Previous Close | 2.6100 |
Open | 2.5900 |
Bid | 2.4400 x 1000 |
Ask | 2.4500 x 900 |
Day's Range | 2.3900 - 2.6300 |
52 Week Range | 2.3700 - 5.1900 |
Volume | 617,900 |
Avg. Volume | 891,161 |
Market Cap | 126.786M |
Beta (5Y Monthly) | 2.26 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.1160 |
Earnings Date | Mar 02, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.25 |
GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that a Phase 1b trial of GMI-1359, being conducted at Duke University Cancer Center, showed evidence of on-target effects, immune-activation and cell mobilization in the initial two patients treated with the Company’s dual antagonist of E-selectin and CXCR4. Dorothy Sipkins, MD, PhD, Associate Research Professor in Pharmacology and Cancer Biology at Duke University School of Medicine, will present results from the proof-of-concept clinical study as well as a separate preclinical study supporting the positive biologic findings of the Phase 1b study. The presentation will be made at the American Association of Cancer Research (AACR) 2021 Annual Meeting, which is being held virtually on April 10-15 and May 17-21. GMI-1359 is GlycoMimetics’ novel small molecule drug candidate, a dual antagonist of E-selectin and CXCR4, designed to target tumor-microenvironment resistance to chemotherapy in cancers with bone metastases.
GlycoMimetics, Inc. (Nasdaq: GLYC) today announces that an abstract presenting the results of a recent preclinical study on the therapeutic effects of GMI-1757, a new glycomimetic with dual antagonism to E-selectin and galectin-3, has been accepted for a poster presentation at the American Association of Cancer Research (AACR) 2021 Annual Meeting, to be held virtually on April 10-15 and May 17-21.
While penny stocks are inherently risky, a knowledge of technical analysis can help you profit from these inexpensive investments.